There were no statistically significant differences between patients with (mMRC ≥ 2) and without (mMRC < 2) disabling dyspnea regarding treatments (23% vs 14%, p = 0.312 for oral antidiabetics; 13% vs 7%, p = 0.312 for insulin; 5% vs 7%, p = 1 for cholesterol-lowering agents; 38% vs 26%, p = 0.148 for antihypertensive drugs) and comorbidities (25% vs 16%, p = 0.225 for diabetes; 18% vs 13%, p = 0.594 for dyslipidemia; 36% vs 25%, p = 0.207 for severe OSAS) except for hypertension (48% vs 28%, p = 0.044). This evidence concerns the gene INS and hypertensive disorder.